EAN 2023 | SUCCESS trial: how do add-on drugs improve the quality of life of PD patients?
Carlo Cattaneo, DBSc CAAAN, Zambon SpA, Bresso, Italy, shares the rationale and design of the SUCCESS trial, an observational, prospective study comparing the effectiveness of safinamide, rasagiline and other “standard of care” drugs as an add-on to levodopa. This real-life study is ongoing and focuses on quality of life, improvement in chronic pain, change in anti-Parkinson’s disease (PD) treatments, use of concomitant painkiller medications, hospitalizations, use of other healthcare resources, and the number of lost workdays. Overall, the SUCCESS study will help evaluate how add-on therapies can improve the quality of life of patients with PD. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The SUCCESS study is an observational trial, it is ongoing, and the aim is to see the effectiveness of the drugs that are on the market for Parkinson disease on the quality of life for patients and their caregivers. Because generally when you register a drug or you measure the efficacy of the drug, you go immediately to see the effects on motor symptoms, sometimes also on non-motor symptoms, but the quality of life generally is not considered...
The SUCCESS study is an observational trial, it is ongoing, and the aim is to see the effectiveness of the drugs that are on the market for Parkinson disease on the quality of life for patients and their caregivers. Because generally when you register a drug or you measure the efficacy of the drug, you go immediately to see the effects on motor symptoms, sometimes also on non-motor symptoms, but the quality of life generally is not considered. Quality of life is very important for the patients because it’s not only important to treat the symptoms, but also to allow the patient to benefit from them, to have good quality of life and good activities of daily living. We are waiting for the results of this study; it is ongoing and we will see how we can improve the quality of life of patients in the future.
Read more...
